Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVBGet Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of NAVB opened at $0.11 on Tuesday. Navidea Biopharmaceuticals has a 52-week low of $0.10 and a 52-week high of $1.05. The company has a market capitalization of $3.92 million, a P/E ratio of -0.22 and a beta of 1.49.

About Navidea Biopharmaceuticals

(Get Rating)

Navidea Biopharmaceuticals, Inc engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Read More

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.